Silver nitrate sclerotherapy for 'clinically significant' chyluria: a prospective evaluation of duration of therapy.
OBJECTIVE
To evaluate and compare the results of regimen A (3 instillations at 8-hourly intervals in 1 day) with the control regimen B (9 instillations at 8-hourly intervals in 3 days) of using 1% silver nitrate solution for renal pelvic instillation sclerotherapy in 'clinically significant' filarial chyluria.


METHODS
Forty-seven patients with clinically significant chyluria attending on 2 different days our urology clinic were prospectively randomized between two groups; the study group received regimen A (n = 21) while the control group received regimen B (n = 26). The variables evaluated included visualization of pyelolymphatic fistulae on retrograde pyelography, hospital stay, outcome and morbidity of the two regimens.


RESULTS
Patients in both groups were comparable for age and sex. The morbidity (fever, symptomatic UTI, hematuria) following regimen A was less than that of regimen B although not statistically significant. The average hospital stay was 3 days for regimen A and 5.5 days for regimen B (p = 0.001). The initial success rate was 80.95% in group A and 92.30% in group B (p = 0.47). The mean duration of follow-up was 15 months (range 9-18). There was no significant difference in recurrence between the two groups during follow-up (group A: 21.05% and group B: 22.72%; p = 0.98).


CONCLUSIONS
Regimen A was as effective as regimen B. Regimen A had the advantages of having less morbidity and shorter duration of hospital stay. We recommend only a 3-instillation regimen in patients with clinically significant chyluria, particularly those who demonstrate pyelolymphatic fistulae on retrograde pyelography.
Dalela
D
D
Department of Urology, King George's Medical University, Lucknow, India. drdalela@satyam.net.in
Rastogi
M
M
Goel
Apul
A
Gupta
Vipul P
VP
Shankhwar
S N
SN
D000328:Adult; D002913:Chyle; D005260:Female; D006801:Humans; D008206:Lymphatic Diseases / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015911:Sclerotherapy; D012835:Silver Nitrate; D013997:Time Factors; D014556:Urine
D012835:Silver Nitrate